BridgeBio Pharma Inc
BBIO76.300USD
+2.160+2.91%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
14.70BMarket Cap
LossP/E TTM
More Details of BridgeBio Pharma Inc Company
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
BridgeBio Pharma Inc Info
Ticker SymbolBBIO
Company nameBridgeBio Pharma Inc
IPO dateJun 27, 2019
CEOKumar (Neil)
Number of employees725
Security typeOrdinary Share
Fiscal year-endJun 27
Address3160 Porter Dr.
CityPALO ALTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94304
Phone16503919740
Websitehttps://bridgebio.com/
Ticker SymbolBBIO
IPO dateJun 27, 2019
CEOKumar (Neil)
Company Executives of BridgeBio Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
--
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
--
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
71.53M
64.70%
Europe Middle East and Africa (EMEA)
35.05M
31.70%
Asia Pacific (APAC)
3.98M
3.60%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.72%
Viking Global Investors LP
8.25%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.19%
Janus Henderson Investors
4.54%
Other
65.43%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.72%
Viking Global Investors LP
8.25%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.19%
Janus Henderson Investors
4.54%
Other
65.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.82%
Investment Advisor/Hedge Fund
34.09%
Hedge Fund
14.83%
Private Equity
8.88%
Individual Investor
4.70%
Research Firm
2.96%
Venture Capital
1.72%
Sovereign Wealth Fund
1.02%
Bank and Trust
0.44%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
692
193.26M
104.83%
+271.46K
2025Q3
709
193.09M
107.21%
-2.36M
2025Q2
651
195.61M
105.27%
+8.34M
2025Q1
612
193.54M
102.70%
-1.78M
2024Q4
570
182.80M
101.77%
+5.04M
2024Q3
551
177.77M
103.84%
-1.98M
2024Q2
526
180.27M
100.67%
+2.80M
2024Q1
514
177.44M
98.44%
-3.39M
2023Q4
509
170.23M
101.76%
+4.36M
2023Q3
504
165.95M
97.66%
+12.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
16.45M
8.61%
+1.58M
+10.64%
Jun 30, 2025
Viking Global Investors LP
17.78M
9.3%
-822.74K
-4.42%
Aug 14, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.94%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.89M
6.22%
+714.59K
+6.39%
Jun 30, 2025
Janus Henderson Investors
9.28M
4.85%
+2.11M
+29.35%
Jun 30, 2025
Farallon Capital Management, L.L.C.
7.90M
4.13%
+2.17M
+37.85%
Jun 30, 2025
Kumar (Neil)
6.17M
3.23%
+5.69K
+0.09%
Aug 20, 2025
Aisling Capital Management LP
6.07M
3.17%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.90M
3.08%
+146.98K
+2.56%
Jun 30, 2025
Two Sigma Investments, LP
4.02M
2.1%
+2.91M
+260.34%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
5.74%
Franklin Genomic Advancements ETF
4.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.6%
Virtus LifeSci Biotech Products ETF
2.53%
State Street SPDR S&P Biotech ETF
2.32%
Tema Heart & Health ETF
2.06%
ProShares Ultra Nasdaq Biotechnology
1.67%
Direxion Daily S&P Biotech Bull 3X Shares
1.43%
iShares Health Innovation Active ETF
1.36%
Invesco Nasdaq Biotechnology ETF
1.17%
View more
Tema Oncology ETF
Proportion5.74%
Franklin Genomic Advancements ETF
Proportion4.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.6%
Virtus LifeSci Biotech Products ETF
Proportion2.53%
State Street SPDR S&P Biotech ETF
Proportion2.32%
Tema Heart & Health ETF
Proportion2.06%
ProShares Ultra Nasdaq Biotechnology
Proportion1.67%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.43%
iShares Health Innovation Active ETF
Proportion1.36%
Invesco Nasdaq Biotechnology ETF
Proportion1.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BridgeBio Pharma Inc?
The top five shareholders of BridgeBio Pharma Inc are:
The Vanguard Group, Inc. holds 16.45M shares, accounting for 8.61% of the total shares.
Viking Global Investors LP holds 17.78M shares, accounting for 9.30% of the total shares.
Kohlberg Kravis Roberts & Co. L.P. holds 13.26M shares, accounting for 6.94% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.89M shares, accounting for 6.22% of the total shares.
Janus Henderson Investors holds 9.28M shares, accounting for 4.85% of the total shares.
The Vanguard Group, Inc. holds 16.45M shares, accounting for 8.61% of the total shares.
Viking Global Investors LP holds 17.78M shares, accounting for 9.30% of the total shares.
Kohlberg Kravis Roberts & Co. L.P. holds 13.26M shares, accounting for 6.94% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.89M shares, accounting for 6.22% of the total shares.
Janus Henderson Investors holds 9.28M shares, accounting for 4.85% of the total shares.
What are the top three shareholder types of BridgeBio Pharma Inc?
The top three shareholder types of BridgeBio Pharma Inc are:
The Vanguard Group, Inc.
Viking Global Investors LP
Kohlberg Kravis Roberts & Co. L.P.
The Vanguard Group, Inc.
Viking Global Investors LP
Kohlberg Kravis Roberts & Co. L.P.
How many institutions hold shares of BridgeBio Pharma Inc (BBIO)?
As of 2025Q4, 692 institutions hold shares of BridgeBio Pharma Inc, with a combined market value of approximately 193.26M, accounting for 104.83% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.38%.
What is the biggest source of revenue for BridgeBio Pharma Inc?
In FY2025Q2, the -- business generated the highest revenue for BridgeBio Pharma Inc, amounting to -- and accounting for --% of total revenue.
